Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05282459 · OUTCOME

Red Blood Cell (RBC) Transfusion Independence (RBC TI)

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation · Source last updated 2026-09-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
12 months

What was measured

Clinical response for red blood cells was assessed as the number of participants who were transfusion dependent that achieve red blood cell (RBC) transfusion independence (RBC TI) for for 8 weeks or longer.

Groups in this outcome

Enasidenib Mesylat 100 mg

Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.

Enasidenib Mesylat 200 mg

Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Enasidenib Mesylat 100 mg2
Enasidenib Mesylat 200 mg8

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enasidenib Mesylat 100 mg0Not reportedNot reportedNot reportedNot reported
Enasidenib Mesylat 200 mg0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      8
    units
    Participants
description
Clinical response for red blood cells was assessed as the number of participants who were transfusion dependent that achieve red blood cell (RBC) transfusion independence (RBC TI) for for 8 weeks or longer.
groups
  1. description
    Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.
    id
    OG000
    title
    Enasidenib Mesylat 100 mg
  2. description
    Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.
    id
    OG001
    title
    Enasidenib Mesylat 200 mg
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
12 months
title
Red Blood Cell (RBC) Transfusion Independence (RBC TI)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice